VIVUS Inc. (VVUS) Company Brief
VIVUS Inc. (NASDAQ: VVUS), the Mountain View, California-based biopharmaceutical company, will see its new weight-loss drug come up for review in front of a FDA panel on July 15th. A positive review on 15th July will be a signal that the FDA may approve the company’s weight-loss drug in October this year. This makes the VIVUS stock an interesting play in the next two weeks. VIVUS had filed a New Drug Application (NDA) for its weight-loss drug Qnexa on March 1, 2010.
Earlier on January 11, 2010, the company had announced new data from an analysis of completed Phase 3 study of avanafil, the company’s investigational drug candidate for the treatment of erectile dysfunction.
VIVUS’s success largely depends upon Qnexa, for treatment of obesity, and avanafil, for treatment of erectile dysfunction. This makes the July 15th FDA panel review even more crucial. The response from the FDA panel will determine the future of the company.
In its latest 10Q, the company mentions that Qnexa is combination of drugs that have been individually approved by the FDA. These drugs are commercially available and marketed by other companies and can be substituted for Qnexa. This may lead to Qnexa facing immediate competition, if it is approved by the FDA this year.
The VIVUS stock is down in today’s trading. The stock touched a low of $8.89 today and at last check; it was down 0.73% to $9.53, with volume at 3.30 million.
The VIVUS stock has a 52-week range of $5.55-$13.68. The support levels for the stock are at $9.32, $9.04 and $8.65, while the resistance levels are at $9.99, $10.38 and $10.77.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
- See today’s top stock picks and market analysis
- Want more? Check out the message board buzz for these stocks
- See what newsletters are recommending these stock picks
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
- This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
